CA3030163A1 - Recombinant polypeptides comprising selenocysteine and method for producing the same - Google Patents
Recombinant polypeptides comprising selenocysteine and method for producing the same Download PDFInfo
- Publication number
- CA3030163A1 CA3030163A1 CA3030163A CA3030163A CA3030163A1 CA 3030163 A1 CA3030163 A1 CA 3030163A1 CA 3030163 A CA3030163 A CA 3030163A CA 3030163 A CA3030163 A CA 3030163A CA 3030163 A1 CA3030163 A1 CA 3030163A1
- Authority
- CA
- Canada
- Prior art keywords
- substitution
- position corresponding
- seq
- polypeptide
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 299
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 297
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 296
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 title description 50
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 title description 50
- 235000016491 selenocysteine Nutrition 0.000 title description 50
- 229940055619 selenocysteine Drugs 0.000 title description 50
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 title description 48
- 238000004519 manufacturing process Methods 0.000 title description 19
- 230000001580 bacterial effect Effects 0.000 claims abstract description 71
- 239000000203 mixture Substances 0.000 claims abstract description 42
- 238000000034 method Methods 0.000 claims abstract description 24
- 102000004190 Enzymes Human genes 0.000 claims abstract description 16
- 108090000790 Enzymes Proteins 0.000 claims abstract description 16
- 238000006467 substitution reaction Methods 0.000 claims description 357
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 98
- 125000001554 selenocysteine group Chemical group [H][Se]C([H])([H])C(N([H])[H])C(=O)O* 0.000 claims description 86
- 235000001014 amino acid Nutrition 0.000 claims description 80
- 238000012217 deletion Methods 0.000 claims description 70
- 230000037430 deletion Effects 0.000 claims description 70
- 150000007523 nucleic acids Chemical class 0.000 claims description 59
- 102000039446 nucleic acids Human genes 0.000 claims description 55
- 108020004707 nucleic acids Proteins 0.000 claims description 55
- 239000011669 selenium Substances 0.000 claims description 20
- 230000014425 selenocysteine incorporation Effects 0.000 claims description 17
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 16
- 229910052711 selenium Inorganic materials 0.000 claims description 16
- 241000894006 Bacteria Species 0.000 claims description 14
- 108020005038 Terminator Codon Proteins 0.000 claims description 7
- 101710137500 T7 RNA polymerase Proteins 0.000 claims description 5
- 108091026890 Coding region Proteins 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 241000588724 Escherichia coli Species 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 108010074686 Selenoproteins Proteins 0.000 abstract description 19
- 102000008114 Selenoproteins Human genes 0.000 abstract description 19
- 210000004027 cell Anatomy 0.000 description 35
- 108090000623 proteins and genes Proteins 0.000 description 32
- 238000010348 incorporation Methods 0.000 description 22
- 108020004566 Transfer RNA Proteins 0.000 description 18
- 230000035772 mutation Effects 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 18
- 101100060880 Drosophila melanogaster colt gene Proteins 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 16
- 238000013467 fragmentation Methods 0.000 description 14
- 238000006062 fragmentation reaction Methods 0.000 description 14
- 229940091258 selenium supplement Drugs 0.000 description 14
- 229940024606 amino acid Drugs 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 13
- 125000001314 canonical amino-acid group Chemical group 0.000 description 13
- 230000027455 binding Effects 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 230000012010 growth Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 238000001544 ultraviolet photolysis digestion Methods 0.000 description 9
- 108090000204 Dipeptidase 1 Proteins 0.000 description 8
- 102000006635 beta-lactamase Human genes 0.000 description 8
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 8
- 230000014616 translation Effects 0.000 description 8
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 7
- 235000018417 cysteine Nutrition 0.000 description 7
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 108010022394 Threonine synthase Proteins 0.000 description 6
- 102000004419 dihydrofolate reductase Human genes 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 101150101442 selA gene Proteins 0.000 description 6
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 5
- 101000740458 Enterobacter cloacae Imipenem-hydrolyzing beta-lactamase Proteins 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 5
- 229960003669 carbenicillin Drugs 0.000 description 5
- XIMIGUBYDJDCKI-UHFFFAOYSA-N diselenium Chemical compound [Se]=[Se] XIMIGUBYDJDCKI-UHFFFAOYSA-N 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000006664 bond formation reaction Methods 0.000 description 4
- 238000001819 mass spectrum Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 241000588697 Enterobacter cloacae Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 101150112623 hemA gene Proteins 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 101150093386 prfA gene Proteins 0.000 description 3
- 101150032960 prfB gene Proteins 0.000 description 3
- 101150076832 pstK gene Proteins 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 101150029855 selB gene Proteins 0.000 description 3
- 101150035847 selD gene Proteins 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 102000052866 Amino Acyl-tRNA Synthetases Human genes 0.000 description 2
- 108700028939 Amino Acyl-tRNA Synthetases Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 101100111650 Enterobacter cloacae nmcA gene Proteins 0.000 description 2
- 101100394050 Escherichia coli (strain K12) gyrB gene Proteins 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 239000007993 MOPS buffer Substances 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 101100365384 Mus musculus Eefsec gene Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 241000607715 Serratia marcescens Species 0.000 description 2
- 101100443856 Streptococcus pyogenes serotype M18 (strain MGAS8232) polC gene Proteins 0.000 description 2
- 101100028273 Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145) argF gene Proteins 0.000 description 2
- 101150004068 acrB gene Proteins 0.000 description 2
- 101150014383 adhE gene Proteins 0.000 description 2
- 101150032882 arcB gene Proteins 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 101150094831 cysK gene Proteins 0.000 description 2
- 101150112941 cysK1 gene Proteins 0.000 description 2
- 101150029709 cysM gene Proteins 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 101150008507 dnaE gene Proteins 0.000 description 2
- 101150035285 dnaE1 gene Proteins 0.000 description 2
- 101150003155 dnaG gene Proteins 0.000 description 2
- -1 for example Chemical compound 0.000 description 2
- 101150101609 ftsA gene Proteins 0.000 description 2
- 101150071760 ftsL gene Proteins 0.000 description 2
- 229940022353 herceptin Drugs 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 101150048280 ocd gene Proteins 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- 101150047781 ptcA gene Proteins 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102220570814 Deoxynucleotidyltransferase terminal-interacting protein 1_H153Y_mutation Human genes 0.000 description 1
- 102220521138 Dihydrofolate reductase_V21A_mutation Human genes 0.000 description 1
- 101100378121 Drosophila melanogaster nAChRalpha1 gene Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 101100106709 Escherichia coli (strain K12) yphG gene Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100490139 Mus musculus Acer3 gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101000655985 Plasmodium falciparum (isolate FCH-5) Thioredoxin reductase Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101000772462 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Thioredoxin reductase 1 Proteins 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 101100135781 Sulfurisphaera tokodaii (strain DSM 16993 / JCM 10545 / NBRC 100140 / 7) pcn2 gene Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 108010013829 alpha subunit DNA polymerase III Proteins 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 101150008808 mdfA gene Proteins 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 101150091444 ompR gene Proteins 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 101150114893 oxyR gene Proteins 0.000 description 1
- 101150069193 pcnB gene Proteins 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 101150067424 queE gene Proteins 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 239000007320 rich medium Substances 0.000 description 1
- 102220231105 rs1064794671 Human genes 0.000 description 1
- 102200102165 rs121908313 Human genes 0.000 description 1
- 102200155728 rs121918462 Human genes 0.000 description 1
- 102200093466 rs137853247 Human genes 0.000 description 1
- 102220294854 rs1553614409 Human genes 0.000 description 1
- 102200021784 rs1556235551 Human genes 0.000 description 1
- 102220035181 rs199475804 Human genes 0.000 description 1
- 102220267326 rs371110225 Human genes 0.000 description 1
- 102220127702 rs375743726 Human genes 0.000 description 1
- 102200110490 rs62654397 Human genes 0.000 description 1
- 102200108206 rs756233241 Human genes 0.000 description 1
- 102220266564 rs763031937 Human genes 0.000 description 1
- 102220069977 rs794727788 Human genes 0.000 description 1
- 102200063471 rs869312821 Human genes 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- FLKWPETUFDRUCE-UHFFFAOYSA-N seleninic acid Chemical compound O[SeH]=O FLKWPETUFDRUCE-UHFFFAOYSA-N 0.000 description 1
- 229940082569 selenite Drugs 0.000 description 1
- MCAHWIHFGHIESP-UHFFFAOYSA-L selenite(2-) Chemical compound [O-][Se]([O-])=O MCAHWIHFGHIESP-UHFFFAOYSA-L 0.000 description 1
- 150000003346 selenoethers Chemical class 0.000 description 1
- WBRSXICUEVGXAB-UHFFFAOYSA-N selenonic acid Chemical compound O[SeH](=O)=O WBRSXICUEVGXAB-UHFFFAOYSA-N 0.000 description 1
- 150000003962 selenoxides Chemical class 0.000 description 1
- GYSDUVRPSWKYDJ-UHFFFAOYSA-N selinone Chemical compound C1=CC(OCC=C(C)C)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 GYSDUVRPSWKYDJ-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- 101150075472 ycf27 gene Proteins 0.000 description 1
- 101150000568 ydiL gene Proteins 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/86—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides, e.g. penicillinase (3.5.2)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Oncology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662360745P | 2016-07-11 | 2016-07-11 | |
| US62/360,745 | 2016-07-11 | ||
| PCT/US2017/041373 WO2018013481A1 (en) | 2016-07-11 | 2017-07-10 | Recombinant polypeptides comprising selenocysteine and method for producing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3030163A1 true CA3030163A1 (en) | 2018-01-18 |
Family
ID=60953318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3030163A Pending CA3030163A1 (en) | 2016-07-11 | 2017-07-10 | Recombinant polypeptides comprising selenocysteine and method for producing the same |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11155804B2 (enExample) |
| EP (1) | EP3481945A4 (enExample) |
| JP (2) | JP7269648B2 (enExample) |
| CN (1) | CN109844105A (enExample) |
| CA (1) | CA3030163A1 (enExample) |
| WO (1) | WO2018013481A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3034701A1 (en) | 2016-08-30 | 2018-03-08 | Board Of Regents, The University Of Texas System | Production of seleno-biologics in genomically recoded organisms |
| CN109486802B (zh) * | 2018-12-26 | 2020-08-04 | 广州白云山拜迪生物医药有限公司 | 一种酶活提高的青霉素酶突变体及其构建方法 |
| WO2025024577A1 (en) * | 2023-07-24 | 2025-01-30 | Board Of Regents, The University Of Texas System | Incorporating unnatural amino acids using one pot pure system |
| CN120158456A (zh) * | 2023-10-18 | 2025-06-17 | 河南农业大学 | 玉米ZmmtRF2a基因突变标记、鉴定引物及其在调控籽粒发育中的应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10309193A (ja) | 1997-05-12 | 1998-11-24 | Sankyo Co Ltd | 哺乳類セレノシステイン含有タンパク質の大腸菌での製造法 |
| US6849417B1 (en) | 1998-04-06 | 2005-02-01 | The United States Of America As Represented By The Department Of Health And Human Services | Mammalian selenoprotein differentially expressed in tumor cells |
| AU6987200A (en) * | 1999-08-16 | 2001-03-13 | Karolinska Innovations Ab | Methods and means for selenoprotein expression |
| US20060051851A1 (en) | 2001-09-13 | 2006-03-09 | Sara Kaminaka | Novel selenocysteine-containing protein |
| WO2007075438A2 (en) | 2005-12-15 | 2007-07-05 | Codon Devices, Inc. | Polypeptides comprising unnatural amino acids, methods for their production and uses therefor |
| CN101965363A (zh) | 2006-11-02 | 2011-02-02 | 丹尼尔·J·卡鹏 | 具有活动部分的杂合免疫球蛋白 |
| WO2009043051A2 (en) | 2007-09-27 | 2009-04-02 | Biogen Idec Ma Inc. | Cd23 binding molecules and methods of use thereof |
| KR101656107B1 (ko) | 2007-11-20 | 2016-09-08 | 암브룩스, 인코포레이티드 | 변형된 인슐린 폴리펩티드 및 이의 용도 |
| MX2013008736A (es) | 2011-01-28 | 2013-11-22 | Ca Nat Research Council | Diseño de dominios de inmunoglobulina. |
| DK2717898T3 (en) * | 2011-06-10 | 2019-03-25 | Bioverativ Therapeutics Inc | COAGULATING COMPOUNDS AND PROCEDURES FOR USE THEREOF |
| US10240158B2 (en) | 2011-07-11 | 2019-03-26 | Yale University | Compositions and methods for making selenocysteine containing polypeptides |
| US9464288B2 (en) | 2011-07-11 | 2016-10-11 | Yale University | Compositions and methods for making selenocysteine containing polypeptides |
| US10876142B2 (en) | 2011-07-11 | 2020-12-29 | Yale University | Compositions and methods for making selenocysteine containing polypeptides |
| EP2968552B1 (en) | 2013-03-14 | 2020-03-11 | The Scripps Research Institute | Targeting agent antibody conjugates and uses thereof |
| US20150050682A1 (en) | 2013-08-15 | 2015-02-19 | University Of Vermont And State Agricultural College | Direct assay of thioredoxin reductase activity |
| WO2015066543A1 (en) | 2013-11-01 | 2015-05-07 | Board Of Regents, The University Of Texas System | Targeting her2 and her3 with bispecific antibodies in cancerous cells |
| US10118950B2 (en) | 2014-08-30 | 2018-11-06 | Northwestern University | Platforms for cell-free protein synthesis comprising extracts from genomically recoded E. coli strains having genetic knock-out mutations in release factor 1 (RF-1) and endA |
| WO2016172269A2 (en) | 2015-04-20 | 2016-10-27 | University Of Utah Research Foundation | Insulin analogs having shortened b chain peptides and associated methods |
| US10557160B2 (en) | 2015-12-15 | 2020-02-11 | Board Of Regents, The University Of Texas System | Transgenic bacteria with expanded amino acid usage and nucleic acid molecules for use in the same |
| AU2017298565B2 (en) | 2016-07-22 | 2021-08-19 | The Walter And Eliza Hall Institute Of Medical Research | Insulin analogs |
| CA3034701A1 (en) | 2016-08-30 | 2018-03-08 | Board Of Regents, The University Of Texas System | Production of seleno-biologics in genomically recoded organisms |
-
2017
- 2017-07-10 CN CN201780048121.5A patent/CN109844105A/zh active Pending
- 2017-07-10 US US16/316,768 patent/US11155804B2/en active Active
- 2017-07-10 WO PCT/US2017/041373 patent/WO2018013481A1/en not_active Ceased
- 2017-07-10 EP EP17828247.1A patent/EP3481945A4/en active Pending
- 2017-07-10 JP JP2019500781A patent/JP7269648B2/ja active Active
- 2017-07-10 CA CA3030163A patent/CA3030163A1/en active Pending
-
2023
- 2023-02-28 JP JP2023029563A patent/JP2023060001A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP3481945A1 (en) | 2019-05-15 |
| EP3481945A4 (en) | 2020-07-29 |
| JP2023060001A (ja) | 2023-04-27 |
| JP2019520083A (ja) | 2019-07-18 |
| JP7269648B2 (ja) | 2023-05-09 |
| WO2018013481A1 (en) | 2018-01-18 |
| CN109844105A (zh) | 2019-06-04 |
| US11155804B2 (en) | 2021-10-26 |
| US20190316110A1 (en) | 2019-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101856792B1 (ko) | 폴리펩티드 다량체를 정제하기 위한 폴리펩티드의 개변방법 | |
| JP6932693B2 (ja) | カッパ及びラムダ軽鎖を含む抗原結合ポリペプチド構築物及びその使用 | |
| KR102168733B1 (ko) | 중쇄와 경쇄의 회합이 제어된 항원 결합 분자 | |
| CN103429737B (zh) | 细胞毒诱导治疗剂 | |
| JP2023060001A (ja) | セレノシステインを含む組換えポリペプチド及びその製造方法 | |
| US20230303694A1 (en) | Antibodies that bind gamma-delta t cell receptors | |
| US20210171609A1 (en) | Method for protein purification | |
| CN119630697A (zh) | Ph依赖性hsa结合分子及使用方法 | |
| JP2020114217A (ja) | ＦｃＲｎ相互作用が変更された抗体を選択するための方法 | |
| EP4292610A1 (en) | Variant antibodies that bind gamma-delta t cell receptors | |
| US12428496B2 (en) | Antibodies, compositions for use in detecting or capturing a polypeptide in a sample, and methods for detecting or capturing a polypeptide in a sample | |
| HK40008291A (en) | Recombinant polypeptides comprising selenocysteine and method for producing the same | |
| CN115956124A (zh) | 改善蛋白质表达的方法 | |
| EP4292609A1 (en) | Compositions comprising antibodies that bind gamma-delta t cell receptors | |
| JP2022060048A (ja) | 抗体及びその使用 | |
| RU2779602C2 (ru) | Устойчивые мультиспецифические антитела | |
| CN120424216A (zh) | 一种抗cd123抗体及其用途 | |
| TW202535947A (zh) | ＣＤ３３抗體、ＣＤ３３／Ｖδ２多特異性抗體及其用途 | |
| WO2025086263A1 (zh) | 抗Taq DNA聚合酶单克隆抗体及其应用 | |
| CN117999286A (zh) | 用于治疗癌症的CD33 x Vδ2多特异性抗体 | |
| HK1188254A (en) | Cytotoxicity-inducing therapeutic agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220425 |
|
| EEER | Examination request |
Effective date: 20220425 |
|
| EEER | Examination request |
Effective date: 20220425 |
|
| EEER | Examination request |
Effective date: 20220425 |
|
| EEER | Examination request |
Effective date: 20220425 |
|
| EEER | Examination request |
Effective date: 20220425 |
|
| EEER | Examination request |
Effective date: 20220425 |
|
| EEER | Examination request |
Effective date: 20220425 |